Share Twitter LinkedIn Facebook Email Michael Wang, MD @michaelwangmd of @MDAndersonNews discusses KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL): results of the phase 2 ZUMA-2 study.
2024 Update on Lymphoma Treatment: Navigating the Latest Advances – Elizabeth Brem, MD [38 Slides] Hodgkin Lymphoma 4 Mins Read
Brentuximab Vedotin, Ipilimumab, + Nivolumab Combination Hodgkin Lymphoma [ASH 2023] Hodgkin Lymphoma 2 Mins Read